diff --git a/wiki/pages/description.html b/wiki/pages/description.html
index 66009667b8975c41a47585cf8581cd96828d95d8..dc5c8b2322f274788ff5bda1dfa2a95c69152bda 100644
--- a/wiki/pages/description.html
+++ b/wiki/pages/description.html
@@ -54,6 +54,7 @@ To make this decision, we conducted extensive research, consulted with experts,
 <br>
 
 <p style="font-size:16px; font-weight:500;"> We have designed and tested three biological devices with potential efficacy. These parts are designed to oxidize TMA into TMAO. To learn more, I invite you to visit our <a href="https://2023.igem.wiki/fsu/engineering">Engineering Success Page</a>. </p>
+<br><center><img src="https://static.igem.wiki/teams/4680/wiki/engineering-images/engineering-images/home/esp.png" height="100%"></center>
 
 <br>
 
@@ -61,14 +62,7 @@ To make this decision, we conducted extensive research, consulted with experts,
 <br>
 <p style="font-size:16px; font-weight:500;">The 2014 Paris Bettencourt team addressed Trimethylaminuria in their project. They engineered “BBa_K1403015”, a part that degraded TMA into TMAO. They used an indirect colorimetric assay as their proof of concept for the functionality of their part. We built upon their work by modifying their part and creating two more of our own to test. We employed the use of both tandem mass spectroscopy and HPLC as our assays of choice. </p>
 <br>
-
-
-
-          <br>
-
-          <center><img src="https://static.igem.wiki/teams/4680/wiki/engineering-images/engineering-images/home/esp.png" height="100%"></center>
-
-        
+          <br>        
           <div class="safety-container" style="background-color: #DDD89A; left:200px; color:black; margin:20px; top:10px; height:60px; padding-top:5px;text-align: center; border-radius: 25px;">
             <h1 style="font-family: 'Passion One', sans-serif; letter-spacing: 0.05em; padding-top:10px;">Our Mission</h1>
           </div>